New Pentagon-NIH Biodefense Partnership Sparks Fears of Defense Department Diverting Medical Research Funds

The Pentagon and the National Institutes of Health (NIH) have entered into a collaborative agreement focused on biodefense and pandemic preparedness, a move that has drawn sharp criticism from congressional Democrats. Lawmakers on Capitol Hill have warned that the arrangement could enable the Defense Department to bypass legislative oversight and divert billions of dollars intended for infectious disease research.

A copy of the agreement, obtained by The New York Times, centers on chemical and biological defense research. While the document does not explicitly outline a total funding figure or specify which projects will be included, individuals familiar with the deal speaking on anonymity suggested that it could involve up to $2 billion from the National Institute of Allergy and Infectious Diseases (NIAID)—representing roughly one-third of the agency’s budget.

Democrats in Congress, who publicized the agreement, expressed deep concern that it would permit Pentagon officials to redirect funds allocated by lawmakers for health agency programs toward the Defense Department’s own priorities. This concern is heightened by the administration’s history of circumventing congressional spending authority, including canceling federal grants and utilizing interagency agreements to undermine other departments, such as the Education Department.

“The interagency agreement needs to be terminated immediately,” stated Representative Rosa DeLauro of Connecticut, the ranking Democrat on the House Appropriations Committee. “These funds were provided for lifesaving medical research, not as extra money for the Department of Defense.”

Senator Patty Murray of Washington, the top Democrat on the Senate Appropriations Committee, accused the Defense Department of “trying to rob the NIH of billions of dollars that Congress provided for medical research so that it can pad the Pentagon’s budget.”

Administration officials, however, denied these allegations.

Dr. Jay Bhattacharya, the director of the NIH, defended the partnership on Friday via social media, asserting that “far from siphoning money away from research, this partnership between the NIH and the Department of War focuses on research projects that will drive discoveries to improve the health of American citizens and members of the military.”

“Led by the National Institute of Allergy and Infectious Diseases, all work will be 100% aligned with our public health mission,” Bhattacharya added.

Kush Desai, a White House spokesman, also clarified on social media that “the NIH is not transferring any money to the Pentagon. This is a project-by-project research partnership.” He accused Representative DeLauro of distorting the facts of the arrangement to score “political points.”

The Pentagon did not immediately respond to a request for comment.

The timing of this agreement coincides with a period of significant turbulence and uncertainty at the National Institute of Allergy and Infectious Diseases. Under the current administration, the institute has experienced substantial leadership turnover and major strategic shifts, moving away from biodefense and pandemic preparedness research that historically stood as one of its three core areas of focus.

In January, leaders of the NIH outlined a new vision for the institute in the journal Nature Medicine, arguing that the agency’s past work on pandemic preparedness “clearly neither prevented the pandemic nor prevented Americans from experiencing among the highest levels of all-cause excess mortality in the developed world during that time.”

Historically, the institute played a leading role in the scientific response to the pandemic, with its longtime director, Dr. Anthony S. Fauci, serving as the public face of many pandemic policies. While the agency was instrumental in the rapid development of vaccines credited with saving millions of lives, it has since become a highly polarized political target.

In the past, approximately one-third of the agency’s roughly $6.6 billion budget was allocated to biodefense and emerging pathogen research. However, in a recent strategic plan, the term “biodefense” was notably absent.

The agreement was signed by Dr. Bhattacharya and Dr. Robert Kadlec of the Defense Department. Dr. Kadlec previously served as the assistant secretary for preparedness and response at the Department of Health and Human Services and played a central role in Operation Warp Speed, the federal initiative to rapidly develop vaccines and therapeutics against Covid-19.

A spokesperson for the Department of Health and Human Services, Madeline Meeker, stated in a statement that such collaborations could “support the development of medical technologies, such as therapeutics, diagnostics, and personal protective equipment, to protect against infectious diseases and other health risks that Americans face,” citing the response to the Ebola outbreak as a key example.

This initiative comes as the Pentagon seeks a substantial budget increase. The administration has requested $1.5 trillion in total, which includes a $350 billion funding tranche routed through the partisan reconciliation process.

Both funding requests are currently stalled on Capitol Hill. Democrats opposing the conflict in Iran have refused to approve additional Pentagon funding through the standard bipartisan appropriations process, while Senate Republicans remain divided over the budget plan required to initiate the reconciliation process.

Last year, congressional Republicans included $150 billion in additional Pentagon funding within their major tax and spending cut legislation.

Helene Cooper contributed reporting.

Source link